What Chai Discovery Announced About the argenx Immunology Collaboration
Chai Discovery said on 15 July 2026 that it entered a collaboration agreement with argenx, giving argenx early access to its platform for designing antibodies from scratch against therapeutic targets. The company describes Chai-2 as the first zero-shot antibody design platform to reach double-digit experimental hit rates, and says its newer Chai-3 model improves on therapeutic binding, hard-to-drug targets, multispecific design, developability and generalisation. No financial terms are stated.
Why the Chai Discovery and argenx Collaboration Matters to Antibody Developers
A double-digit hit rate for designing an antibody with no prior examples would be a genuine change, because traditional discovery screens enormous libraries to find a few that bind. The figure is the company's own and the word to watch is experimental: it means something was made and tested, which is a higher bar than a computational score, but it is still Chai's own bench rather than an independent one. argenx is an antibody company with its own strong discovery engine, so it choosing to evaluate this is a more informative signal than a general technology partnership.
Where the Chai Discovery Update Comes From
Chai Discovery is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
Chai Discovery original source.
How We Would Research the Chai Discovery argenx Collaboration
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would ask Chai Discovery for the published data behind the double-digit hit rate, including how many targets and how hit was defined.
- Then we would ask argenx how the platform performed against its own in-house discovery on the same target.
- We would separate Chai-2 from Chai-3 in every claim, since the hit rate figure belongs to the older model.